María José S. L.
- Country
- Spain
- Department
- ONCOLOGIA
Research Overview
- Efficacy and Safety of Oral Decitabine and Ivosidenib in Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
- Comparison of Seven-Day versus Continuous Venetoclax Exposure with Azacitidine in Treatment-Naïve Patients with Ineligible-for-Intensive Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 7 of 25 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of acute myeloid leukemia, with particular emphasis on developing innovative therapeutic approaches for newly diagnosed patients.
- Blood Cancer Therapeutics
- Leukemia Treatment Protocols
- Combination Therapy Approaches
Their research encompasses the evaluation of novel treatment combinations incorporating chemotherapy and targeted therapeutic agents.
Targeted Therapeutics
The investigator focuses on developing treatment strategies for FLT3-ITD negative AML patients, exploring the potential of targeted therapies in combination with standard treatments.
- Molecular Targeting
- Treatment Optimization
- Drug Resistance Mechanisms
Their work includes investigation of therapeutic agents that may enhance the efficacy of conventional chemotherapy regimens.
Treatment Innovation
The investigator's research interests include the development of maintenance therapy protocols and evaluation of long-term treatment strategies in hematologic malignancies.
- Novel Treatment Protocols
- Clinical Outcomes Assessment
- Survival Analysis
Their work encompasses the evaluation of extended treatment approaches to improve patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.